FDA Issues Not-Approvable Letter For Lilly's Zyprexa® Long-Acting Injection (LAI) For S
FDA Issues Not-Approvable Letter For Lilly's Zyprexa® Long-Acting Injection (LAI) For S
|
Eli Lilly and Company (NYSE: LLY) has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa® long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced. |
read more...
News entry number 4146 added on Mar 3, 2008 in the Health category.
Comenteaza
Other News in the Health category
Categorie:
Categorie:
Categorie:
Categorie:
Categorie:
Related Links
- Business Briefing: Sainsbury's shares pass sell-by date as Qatari group pulls out of takeover
- FDA Licenses 15 New Blood Typing Tests - Tests Help Ensure Safe Blood Transfusions For Patients
- Missing girl's mom says she was pressured to confess
- FDA Approves New Uses For Evista - Drug Reduces Risk Of Invasive Breast Cancer In Postmenopausal
- This Time, Illinois Is the Team That Spoils Ohio State’s Season
- Missing 4-year-old Madeleine McCann's parents return to England as suspects in the case
- Success or mess? Congress set to judge U.S. Iraq policy
- Angus Fraser: Confusion over Flintoff's fitness clouds Moores' Twenty20 vision
- Canada's greenhouse-gas emissions rose sharply between 1990 and 2005: study
News Categories
745
523
480
347
1011
693
280
973
Top 10 News
- Texas Woman Claims to Have Found Mythical 'Chupacabra'
- Google Starts Hosting News on Website
- Study Focuses On Cancer Risk In Biologic Treatment For Rheumatoid Arthritis
- Wireless technology hits security budgets
- Google forced to push image in China
- Ho-hum, the guest's another candidate
- Microsoft purchase of RIM nice to consider, but unlikely
- Western School Board limits digital devices
- 'Spooky' science points to quantum internet
- Nuñez, gov. gamble on healthcare overhaul
Statistics
News:
News Categories:
News Read:
News Categories:
News Read:
5052
8
617
8
617